In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant

Researchers reported an in situ CAR-macrophage therapy via codelivery of mRNA and immunostimulant. By leveraging lipid nanoparticles designed to selectively transfect tumor-associated macrophages, they circumvent extensive ex vivo manipulation and achieve robust CAR expression directly within the tumor microenvironment.